RxDoctor Payments Data

Lior Hirsch, MD

Urology · Philadelphia, PANPI 1508251869

Payments from drug & device makers

$7,895in general payments, 2019–2025

Across 240 payments — averaging $32.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Dendreon Pharmaceuticals LLC$804
  • Medical Device Business Services, Inc.$680
  • Johnson & Johnson$586
  • Astellas Pharma US Inc$546
  • Pfizer$343
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$7,18091%
  • Education$7159%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,895 in reported general payments places this provider in the 75th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$374,030
Medicare patients
989
Services billed
9,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide72$972,902
OrgovyxRelugolix235$612,111
Abiraterone Acetate56$109,654
MyrbetriqMirabegron123$75,890
GemtesaVibegron47$31,571
Mirabegron ErMirabegron15$9,567
Tamsulosin Hcl759$7,795
Methenamine Hippurate54$5,576
Finasteride333$3,795
Silodosin13$1,454
Potassium Citrate ErPotassium Citrate16$1,396
Dutasteride18$1,189
Alfuzosin Hcl ErAlfuzosin Hcl62$937
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$543
Prednisone60$395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$546$1,048,793195 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$256$643,681282 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 596 urology providers in Pennsylvania.

Other urology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →